Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2011

View Archived Issues

Spotlight on myotonic dystrophy: Misregulated alternative BIN1 splicing linked to muscle weakness

Novel antineoplastic agents presented

Topline phase III data on HyQ in primary immunodeficiency

NVP-BEZ-235/everolimus combination displays synergistic antitumor effects in models of NSCLC

CUPID trial supports safety and efficacy of Mydicar intracoronary gene therapy for heart failure

Niclosamide inhibits protein involved in colon cancer metastasis

Rectogesic slows lymphatic transit time of snake venom

Boehringer Ingelheim patents novel chemokine CCR2 receptor antagonists

New nicotinic acetylcholine alpha7 receptor ligands presented by NeuroSearch

Novel metabotropic mGlu5 glutamate receptor modulators developed

Novartis synthesizes new orexin receptor antagonists

French universities patent new agents for herpes simplex virus infection

Evotec and UCB form drug discovery collaboration for CNS disorders

NovaBay Pharmaceuticals provides pipeline update

Sinapis Pharma completes phase I trial of methamphetamine hydrochloride

Mesoblast receives FDA clearance for phase III bone marrow regeneration trial

Novartis initiates phase II LCQ-908 trial in hepatitis C

Achillion begins phase I trial of ACH-2928 for treatment of hepatitis C

Resminostat receives FDA orphan status in hepatocellular cancer

Eisai Europe reports phase III results showing efficacy of zonisamide in newly diagnosed epilepsy

Ildong Pharmaceutical to sell pirfenidone in South Korea under license agreement with Shionogi

Genfit reports encouraging phase II data on GFT-505 in diabetes

Treatment begins in phase Ib Ampion trial in osteoarthritis of the knee

Ipsen and Institut de cancerologie Gustave Roussy sign 3-year oncology partnership

PharmaVentures to assist Avexa in out-licensing apricitabine for HIV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...